EI

251.2

-0.83%↓

SAN

81.4

+0.28%↑

SHL.DE

45.79

-0.93%↓

ARGX

548.8

-1.72%↓

PHIA

23.14

+0.74%↑

EI

251.2

-0.83%↓

SAN

81.4

+0.28%↑

SHL.DE

45.79

-0.93%↓

ARGX

548.8

-1.72%↓

PHIA

23.14

+0.74%↑

EI

251.2

-0.83%↓

SAN

81.4

+0.28%↑

SHL.DE

45.79

-0.93%↓

ARGX

548.8

-1.72%↓

PHIA

23.14

+0.74%↑

EI

251.2

-0.83%↓

SAN

81.4

+0.28%↑

SHL.DE

45.79

-0.93%↓

ARGX

548.8

-1.72%↓

PHIA

23.14

+0.74%↑

EI

251.2

-0.83%↓

SAN

81.4

+0.28%↑

SHL.DE

45.79

-0.93%↓

ARGX

548.8

-1.72%↓

PHIA

23.14

+0.74%↑

Search

Almirall SA

Open

SectorGezondheidszorg

10.24 -1.54

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

10.3

Max

10.46

Belangrijke statistieken

By Trading Economics

Inkomsten

-31M

5M

Verkoop

-12M

274M

K/W

Sectorgemiddelde

103.6

34.393

EPS

0.1

Dividendrendement

1.84

Winstmarge

1.815

Werknemers

2,084

EBITDA

32M

76M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+16.99% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

1.84%

2.54%

Volgende Winsten

10 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-94M

2.2B

Vorige openingsprijs

11.78

Vorige sluitingsprijs

10.24

Nieuwssentiment

By Acuity

50%

50%

162 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Almirall SA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 dec 2024, 07:05 UTC

Marktinformatie

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Peer Vergelijking

Prijswijziging

Almirall SA Prognose

Koersdoel

By TipRanks

16.99% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 12.05 EUR  16.99%

Hoogste 14 EUR

Laagste 10.5 EUR

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Almirall SA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

3

Buy

3

Hold

0

Sell

Technische score

By Trading Central

9.76 / 10.2Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Strong Bullish Evidence

Sentiment

By Acuity

162 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Almirall SA

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.